02:02:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.

Kalender

2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021
2021-11-16 22:08:31

BRAIN+ A/S (BRAINP)

Company Announcement No. 3-2021

Tuesday November 16, 2021, 22:05 CET

Kim Arvid Nielsen, who has served as a Board member at Brain+ for about 2 years has chosen to focus his time and to go full time into his orignial profession of being a medical doctor/general practitioner. Kim A. has therefore decided to announce his intention to leave his position as Board member but will continue to serve on the Board until his replacement is found.

Lars Terney, Chairman of the Board, comments: "The board would like to thank Kim A. for his contributions and wholeheartedly respect Kim A's assessment that the time requirement of the Brain+ board work is non compatible with his future career aspirations. We wish Kim A. all the best in the future and thank him profoundly for his contributions."
 

This press release constitutes inside information that Brain+ A/S is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out below, at the time stated by the Company's news distributor, Cision, at the publication of this press release.

Contact Information

The Company:

CEO, Kim Baden-Kristensen + 45 31393318
E-mail: kim@brain-plus.com
Brain+ A/S
Købmagergade 53, 3.

Certified Advisor:

Keswick Global AG
+ 43 1 740 408045 
E-mail: info@keswickglobal.com

About BRAIN+ [BRAINP]

The mission of Brain+ is to restore patients' independence and quality of life by treating and detecting cognitive decline in Alzheimer's disease and dementia through digital means. Brain+ has developed a set of Digital Medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, Brain+ is in a strong position to grow towards a market leader position in the major Digital Medicine space.